Materials and methods for controlling iron trapping pathogens
By introducing iron trapping components in the environment of pathological microbial growth, the problem of difficulty in obtaining iron trapping pathogens in the host is solved, inhibiting pathogenicity and destruction of biofilms are achieved, and anti-infection efficacy is improved.
Patent Information
- Application Number
- CN202380052594.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-07-08
- Filing Date
- 2023-07-07
- Publication Date
- 2025-03-14
AI Technical Summary
Iron capture pathogens have difficulty obtaining iron in the host, resulting in reduced pathogenicity. The existing antibiotics are low in efficacy against infection in biofilm state and have increased drug resistance.
A composition containing an iron trap component is provided, introduced into an environment for pathological microbial growth, competing with pathogens for iron resources, and inhibiting its pathogenicity. The composition includes strains of beneficial microorganisms such as Bacillus subtilis and their growth byproducts, capable of capturing iron in an acidic environment.
By reducing the pathogenicity of pathogens, it enhances the competition for pathogens by beneficial microorganisms, aggravates the destruction of pathogenic biofilms, and inhibits the growth and virulence of pathogens.
Smart Images

Figure HDA0005233066440000011 
Figure HDA0005233066440000012 
Figure HDA0005233066440000021
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 359,248, filed on July 8, 2022, the contents of which are incorporated herein by reference in their entirety. Background Art
[0003] Iron-trapping pathogens are bacterial pathogens that can acquire iron through receptor-mediated recognition of transferrin, lactoferrin, hemopexin, hemoglobin, or the hemoglobin-haptoglobin complex.
[0004] Vertebrates do not contain free iron, which means that all bacterial pathogens undergo a period of iron deprivation after entering the host. Iron is essential for bacterial and fungal physiological processes, such as, for example, DNA replication, transcription, metabolism, and respiration. Therefore, pathogens rely on iron assimilation as a virulence factor in many aspects. They can obtain iron directly from the host using different strategies, including, for example, the production of extracellular Fe 3+ Chelating molecules, heme uptake and Fe uptake 2+ .
[0005] Some iron-trapping pathogens include, for example, E. coli, Vibrio cholerae, Salmonella enterica, Streptococcus spp., Yersiniapestis, Erwinia amylovora, Haemophilus influenzae, Dickea dadantii, Klebsiella pneumoniae, Staphylococcus aureus, Mycobacterium tuberculosis, Legionella pneumophila, Neisseria meningitidis, Bartonella quintana, Bacillus anthracis, Pseudomonas syringae, and Serratia marcescens.
[0006] As a specific example, Legionella pneumophila is an intracellular pathogen that causes Legionnaires' disease, a severe form of pneumonia. The disease is usually contracted when a subject inhales droplets or swallows water containing the bacteria. L. pneumophila cannot survive without iron. Iron is also key to the microbe's pathogenesis and can be sequestered from host cells through a variety of specialized metabolic pathways.
[0007] As another additional example, Neisseria spp. (e.g., N. meningitidis and N. gonorrhoeae) can cause diseases such as meningitis, sepsis, and gonorrhea. These bacteria have developed mechanisms to capture iron from host proteins such as lactoferrin and transferrin.
[0008] Plants can also be affected by iron-trapping pathogens. For example, Dickeya dadantii is a soft-rot enterobacterium that attacks a variety of plants, including many vegetables and ornamentals, by degrading pectin. These bacteria are found in soil and on plant surfaces and typically enter plants through wound sites or natural openings. D. dadantii produces siderophores that enable the microorganism to acquire iron from the host plant and facilitate systemic infection.
[0009] Therefore, bacterial infections are a ubiquitous problem in human and veterinary medicine, as well as in agriculture. Antibiotics are the most common tool to combat infection; however, their overuse has led to increasing concern about the development of resistant strains of microorganisms. Furthermore, many antibiotics have low or no efficacy against infections in the biofilm state.
[0010] Bacteria in biofilms respond collectively to certain factors that are unique to the biofilm phenotype, resulting in the secretion of an exopolysaccharide (EPS) matrix that surrounds and connects individual cells. Biofilms behave differently than the same bacteria in free-floating form. They are much less susceptible to antimicrobials, making certain infections such as pneumonia difficult to treat or even potentially fatal. Furthermore, because antimicrobials fail to eradicate these EPS-protected microbial communities, their use can exacerbate the problem by selecting for and perpetuating increasingly resistant bacteria. These bacteria include methicillin-resistant Staphylococcus aureus (MRSA), the leading cause of nosocomial infections in the world and a bacterium that is now widespread throughout the community.
[0011] Iron-trapping bacteria may be responsible for a range of difficult-to-treat diseases and health conditions in humans, animals, and plants. Iron, or the lack of it, is an essential sensory cue for bacterial pathogens, and it triggers the coordinated regulation of genes involved in iron acquisition and virulence. In addition, biofilms can exacerbate the virulence and difficulty in treating these pathogens. Therefore, new compositions and methods are needed to treat infections in the body, in plants, and on equipment in hospitals, clinics, and operating rooms. Summary of the invention
[0012] The present invention provides compositions and methods for controlling iron-trapping pathogens. More specifically, the present invention provides compositions that, when applied to an environment where iron-trapping pathological microorganisms grow, can modulate the pathogens in a manner that reduces and / or eliminates their pathogenicity. Advantageously, these compositions and methods can be used to treat and / or prevent diseases and infections caused by iron-trapping pathogens.
[0013] In a preferred embodiment, the present invention provides methods for controlling iron-trapping pathogens, wherein a composition comprising an iron-trapping component is introduced into an environment where pathological microorganisms grow. Thus, the present invention provides methods for controlling pathogens, wherein a composition applied to the environment of a pathogen competes with the pathogen for iron resources. These methods can be used in environments including, for example, human and / or animal subjects, soil, plants, water and / or inanimate surfaces.
[0014] Advantageously, in certain embodiments, these methods result in the capture of iron present in the pathogen's environment, thereby inhibiting its pathogenicity via iron limitation. Thus, in preferred embodiments, these methods result in direct inhibition of the pathogen, increased competition for the pathogen by beneficial microorganisms, disruption of pathogenic biofilms, and / or disruption of one or more biological pathways by which the pathogen utilizes iron for growth, reproduction, and / or virulence.
[0015] In one embodiment, the methods of the invention comprise identifying the presence of an iron-trapping pathogen prior to administering a composition of the invention.
[0016] Non-limiting examples of bacterial pathogens that can utilize one or more iron acquisition systems to enhance virulence of infection include: Escherichia spp. (e.g., Escherichia coli), Vibrio spp. (e.g., Vibrio cholerae, Vibrio vulnificus), Shigella spp. (e.g., Shigella flexneri, Shigella dysenteriae), Salmonella spp. (e.g., Salmonella enterica), Streptococcus spp. (e.g., Streptococcus pyogenes, Streptococcus agalactiae, Group A Streptococcus), Yersinia spp. (e.g., Yersinia pestis), Haemophilus spp. (e.g., Haemophilus influenzae H.influenzae), Klebsiella spp. (e.g., Klebsiella pneumoniae K.pneumoniae), Staphylococcus spp. (e.g., Staphylococcus aureus S.aureus), Mycobacterium spp. (e.g., Mycobacterium tuberculosis M.uberculosis), Neisseria spp. (e.g., Neisseria meningitidis N.meningitidis, Neisseria gonorrhoeae N.gonorrhoeae), Bartonella spp. (e.g., Bartonella quintana B.quintana), Bacillus spp. (e.g., Bacillus anthracis B.anthracis, Bacillus cereus), Serratia spp. (e.g., Serratia marcescens S.marcescens), Pseudomonas spp. (e.g., Pseudomonas aeruginosa P.aeruginosa), Legionella spp. (e.g., Legionella pneumophila L.pneumophila), Meningococcus spp.), Brucella spp. (e.g., Brucella abortus B.abortus), Listeria spp. (e.g., Listeria monocytogenes L.monocytogenes), Acinetobacter spp. (e.g., Acinetobacter baumannii A.baumannii), Francisella spp.(e.g. Francisella tularensis) and / or Haemophilus spp. (e.g. Haemophilus influenzae).
[0017] The present invention also provides a composition comprising one or more components that capture iron. In certain embodiments, the iron-capturing component is a beneficial microorganism, a growth byproduct of an iron-capturing microorganism, or some other compound known to bind iron. In certain embodiments, the composition comprises more than one iron-capturing component.
[0018] In a preferred embodiment, the beneficial microorganisms of the present invention are non-pathogenic fungi, yeasts and / or bacteria that are able to accumulate iron naturally or through genetic modification.
[0019] In one embodiment, the beneficial microorganism is a strain of Bacillus subtilis. In a specific embodiment, the strain is Bacillus subtilis B4 (NRRL B-68031). The B4 strain is preferably applied in the form of spores, but grows in the form of biofilm when exposed to an acidic environment.
[0020] Surprisingly, it was found that B4 produces one or more compounds that can gather, chelate or otherwise capture iron. In certain embodiments, the compound is pulcherrimone and / or pulcherrimone acid. Advantageously, when microorganisms and / or microorganisms' extracellular polysaccharides (EPS) grow in the form of biofilms, these microorganisms and / or microorganisms' extracellular polysaccharides (EPS) when exposed to acidic pH values (e.g., less than 6.8, preferably less than 5.0), use iron-capturing agents (such as pulcherrimone and / or pulcherrimone acid) to store freely available iron.
[0021] B4 is also particularly advantageous compared to other traditional probiotic microorganisms due to its ability to produce digestive enzymes (including, for example, cellulases and amylases).
[0022] In certain embodiments, the composition may include other non-pathogenic microorganisms that are capable of producing compounds that can sequester, chelate or otherwise trap iron. The microorganisms may be in biofilm form, spore form, planktonic form, or any other form.
[0023] In certain embodiments, these microorganisms are also capable of producing one or more of the following: surfactants, such as lipopeptides and / or glycolipids; bioactive substances with antimicrobial and immunomodulatory effects; polyketides; acids; peptides; anti-inflammatory compounds; enzymes, such as amylases, cellulases, proteases and / or lipases; and sources of amino acids, vitamins and other nutrients.
[0024] In certain embodiments, the iron-trapping component of the composition of the present invention is a crude or purified siderophore or plant siderophore, or other molecules with high iron affinity, for example, pulcherrimin, pulcherriminic acid, citrate, citric acid, EDTA (ethylenediaminetetraacetic acid), iron EDTA, DTPA (diethylenetriaminepentaacetic acid), EDDHA (ethylenediamine-di-o-hydroxyphenylacetic acid), N,N-dihydroxy-N,N′-diisopropyladipamide (DPH), 2,3-dihydroxybenzoic acid, azotocin, transferrin, enterocoele bacteriocin, pyocyanin, protochelatin, chelatrocin, bacteriocin, vibriocin, vibrioferrin, azotocin, aminochelatin, yersin, agarobactin, grape agglutinin, ferrochrome, deferasirox, deferiprone, deferoxamine, fusarin, chrysin, chromatin, ornithine, rhodotorulic acid, lysine, glutamic acid, gluconic acid, ferric oxyhydroxide minerals, ferrihydrite, magnetite, hematite, goethite, siderocite, hydroxamate, catecholase, salicylate, carboxylate, mugineic acid, ferulic acid, caffeic acid and / or nicotinamide.
[0025] In certain embodiments, the composition comprises an organic acid or an inorganic acid. Preferably, the acid is present in an amount suitable for adjusting the pH of the composition or the environment in which it is used to 6.8 or lower, preferably 5.0 or lower, more preferably 4.8 or lower.
[0026] In certain embodiments, the composition can be formulated for internal and / or external administration to a human or animal subject, such as an oral formulation, a topical formulation, or an injectable formulation. In other embodiments, the composition can be formulated, for example, as a powder or liquid, for application to plants or soil. In still other embodiments, the composition can be formulated for application to water and / or an inanimate or inert surface, such as a liquid, gel, powder, or aerosol. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figures 1A to 1C Shown are the growth and exopolysaccharide (EPS) formation of B4 after 24 h (A) and 48 h (B) at acidic pH (top row, pH 4.8) and neutral pH (bottom row, pH 6.8).
[0028] Figure 2 The purified B4 EPS is shown to be pink.
[0029] Figure 3 Results of an amylase test of B4 are shown. Agar streaked with B4 produced an orange color around bacterial growth, indicating that starch was broken down.
[0030] Figure 4 Results of the cellulase test of B4 are shown. Agar streaked with B4 produced a yellow clearing zone around bacterial growth, indicating that cellulose was broken down.
[0031] FIG. 5A to FIG. 5C The production and activity of B4 siderophores after 6 hours in aerobic (top panel) and anaerobic (bottom panel) environments and in different growth media are shown. (A) B4 cultures grown in MRS-sucrose (left) medium and B4 cultures grown in M23-6 (right) medium are shown. (B) B4 cultures grown in minimal medium with Tween (left) and minimal medium without Tween (right) are shown. (C) Dry B4 spores grown in minimal medium are shown.
[0032] FIG. 6A to FIG. 6C The production and activity of B4 siderophores after 24 hours in aerobic (top panel) and anaerobic (bottom panel) environments and in different growth media are shown. (A) B4 cultures grown in M23-6 (left) and MRS-sucrose (right) medium are shown. (B) B4 cultures grown in minimal medium with Tween (left) and minimal medium without Tween (right) are shown. (C) Dry B4 spores grown in minimal medium are shown.
[0033] Figure 7 Shown are the results of iron assays of B4 (BSSL) cultures grown in different media. DETAILED DESCRIPTION
[0034] The present invention provides compositions and methods for controlling iron-trapping pathogens. More specifically, the present invention provides a composition that, when applied to an environment where iron-trapping pathological microorganisms grow, can modulate iron-trapping pathogens in a manner that reduces and / or eliminates their pathogenicity.
[0035] Advantageously, in some embodiments, the compositions and methods may also be used to treat and / or prevent disease or infection in humans, plants, or animals caused by iron-trapping pathogens.
[0036] Selected Definitions
[0037] As used herein, "biofilm" is a complex aggregate of microorganisms (such as bacteria) in which cells adhere to each other and / or to a surface. In certain embodiments, adhesion is achieved via extracellular polysaccharide substances produced by the bacteria. Cells in a biofilm are physiologically different from planktonic cells of the same organism, which are single cells that can float or swim in a liquid culture medium.
[0038] As used herein, the term "control" when used in reference to undesirable microorganisms (e.g., pathogens) is meant to extend to killing, disabling, immobilizing and / or reducing the population of the microorganism, and / or otherwise rendering the microorganism incapable of carrying out an undesirable process (e.g., infectious pathogenicity).
[0039] As used herein, "infection" refers to the introduction and / or presence of a disease-causing or pathogenic organism into another organism, tissue, or cell.
[0040] As used herein, "preventing" or "prevention" a disease, condition, or disorder refers to delaying, arresting, inhibiting, preventing, and / or minimizing the onset or progression of specific signs or symptoms thereof. Prevention may include, but does not require, indefinite, absolute, or complete prevention during the lifetime of a subject, meaning that signs or symptoms may still develop later. Prevention may include reducing the severity of the onset of such a disease, condition, or disorder, and / or inhibiting the progression of a condition or disorder to a more severe condition or disorder.
[0041] As used herein, "treating" or "treatment" of a disease, condition, or disorder refers to eradication, improvement, reduction, alleviation, or reversal of at least one sign or symptom of a disease, condition, or disorder (e.g., infection). Treatment may include but does not require complete cure of the disease, condition, or disorder, meaning that treatment may also include partial eradication, improvement, reduction, alleviation, or reversal.
[0042] As used herein, an "isolated" or "purified" nucleic acid molecule, polynucleotide, polypeptide, protein, organic compound such as a small molecule (such as those described below), or other compound is substantially free of other compounds associated with it in nature (e.g., microporous materials). For example, a purified or isolated polynucleotide (ribonucleic acid (RNA) or deoxyribonucleic acid (DNA)) is free of flanking genes or sequences in its naturally occurring state. A purified or isolated polypeptide is free of amino acids or sequences that flank it in its naturally occurring state. A purified or isolated microbial strain is removed from the environment in which it exists in nature. Thus, an isolated strain may exist, for example, as a biologically pure culture or as a spore (or other form of strain) associated with a vector.
[0043] In certain embodiments, the purified compound is at least 60% by weight of the compound of interest. Preferably, the preparation is at least 75% by weight of the compound of interest, more preferably at least 90%, and most preferably at least 99%. For example, the purified compound is at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99% or 100% (w / w) by weight of the desired compound. Purity is measured by any appropriate standard method such as column chromatography, thin layer chromatography or high performance liquid chromatography (HPLC) analytical methods.
[0044] As used herein, "ionophores" are carboxylated polyether non-therapeutic antibiotics, wherein the carboxylated polyether non-therapeutic antibiotics disrupt the ion concentration gradient (Ca2+, K+, H+, Na+) of microorganisms, thereby causing them to enter an ineffective ion cycle. The disruption of ion concentrations makes it impossible for microorganisms to maintain normal metabolism and causes microorganisms to consume additional energy. The functions of ionophores include: selecting against Gram-positive bacteria (such as methanogens) and protists or affecting the metabolism of Gram-positive bacteria and protists.
[0045] As used herein, "siderophores" are compounds produced by various organisms to remove iron from the surrounding environment. Siderophores are generally small, low molecular weight compounds that have the ability to bind to ferric iron (Fe 3+ ) with a higher affinity, thereby forming strong iron chelate complexes that can be taken up by organisms under certain circumstances. As used herein, "plant siderophores" are siderophores produced by plants.
[0046] "Metabolite" refers to any substance produced by metabolism (e.g., a growth byproduct) or a substance necessary to participate in a specific metabolic process. A metabolite can be an organic compound that is a starting material, intermediate, or end product of metabolism. Examples of metabolites can include, but are not limited to, enzymes, toxins, acids, solvents, alcohols, proteins, carbohydrates, vitamins, minerals, trace elements, amino acids, polymers, polyketides, and surfactants.
[0047] As used herein, "methanogens" are microorganisms that produce methane gas as a byproduct of metabolism. Methanogens are archaea that can be found in the digestive systems and metabolic wastes of ruminants and non-ruminants (e.g., pigs, poultry, and horses, among others). Examples of methanogens include, but are not limited to, Methanobacterium spp. (e.g., M. formicicum), Methanobrevibacter spp. (e.g., M. ruminantium), Methanococcus spp. (e.g., M. paripaludis), Methanoculleus spp. (e.g., M. bourgensis), Methanoforens spp. (e.g., M. stordalenmirensis), Methanofollis liminatans, Methanogenium wolfei, Methanomicrobium spp. (e.g., M. mobile), Methanomicrobium candlerii, and Methanomicrobium spp. spp., Methanoregula boonei, Methanosaeta spp. (e.g., M. concilii, M. thermophile), Methanosarcina spp. (e.g., M. barkeri, M. mazeii), Methanosphaera stadtmanae, Methanospirillium hungatei, Methanothermobacter spp., and / or Methanothrix sochngenii.
[0048] The scope provided herein is understood as a shorthand expression of all numerical values in the scope. For example, the scope of 1 to 50 is understood to include any number, combination of numbers or the sub-range of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 and all decimal values (such as, for example, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 and 1.9) between the above integers. About sub-range, " nested sub-range " extending from any end point of scope is particularly considered. For example, nested sub-ranges of the exemplary range 1 to 50 may include 1 to 10, 1 to 20, 1 to 30, and 1 to 40 in one direction, or 50 to 40, 50 to 30, 50 to 20, and 50 to 10 in the other direction.
[0049] As used herein, "decrease" refers to a negative change and "increase" refers to a positive change, wherein the positive or negative change is at least 0.25%, 0.5%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0050] The transitional term "comprising," which is synonymous with "including" or "containing," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. In contrast, the transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of the claim to the specified materials or steps "and those that do not materially affect the basic, novel characteristic." Use of the term "comprising" refers to other embodiments consisting of "consisting of" or "consisting essentially of" the referenced components.
[0051] Unless otherwise specified or obvious from the context, the term "or" as used herein should be understood to be inclusive. Unless otherwise specified or obvious from the context, as used herein, the terms "a", "and" and "the" are understood to be singular or plural.
[0052] Unless otherwise specified or apparent from the context, as used herein, the term "about" should be understood to be within the normal tolerance range in the art, such as within 2 standard deviations of the mean. "About" can be understood to be within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05% or 0.01% of the specified value.
[0053] The recitation of a list of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of the listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0054] All references cited herein are hereby incorporated by reference in their entirety.
[0055] Composition
[0056] In a preferred embodiment, the present invention provides methods for controlling iron-trapping pathogens, wherein a composition comprising an iron-trapping component is introduced into an environment where pathological microorganisms grow. Thus, the present invention provides methods for controlling pathogens, wherein a composition applied to the environment of a pathogen competes with the pathogen for iron resources. These methods can be used in environments including, for example, human and / or animal subjects, soil, plants, water and / or inanimate surfaces.
[0057] The present invention also provides a composition for use according to the method of the present invention, wherein the composition comprises one or more components that capture iron. In certain embodiments, the iron-capturing component is a beneficial microorganism, a growth byproduct of an iron-capturing microorganism, or some other compound known to bind iron. In certain embodiments, the composition comprises more than one iron-capturing component.
[0058] The total amount of iron-trapping components in the composition preferably comprises 0.0001% to 100% of the composition, or 0.001% to 95%, 0.01% to 90%, 0.1% to 85%, 0.5% to 80%, 0.75% to 75%, 1.0% to 70%, 1.25% to 65%, 1.5% to 60%, 1.75% to 55%, 2.0% to 50% or 5.0% to 25% of the composition by weight or by volume.
[0059] In certain embodiments, the composition is a "microbial-based composition," which means that the composition contains components produced by the growth of a microorganism or other cell culture. Thus, a microbial-based composition may include the microorganism itself and / or microbial growth byproducts. The microorganism may be in an asexual state, in spore form, in mycelial form, in any other form of microbial propagule, or a mixture thereof. The microorganism may be in the form of a planktonic microorganism or a biofilm, or a mixture of the two. The byproducts of growth may be, for example, metabolites, cell membrane components, expressed proteins, and / or other cell components. The microorganism may be a complete microorganism or a lysed microorganism. The cells may be completely absent, or present in an amount of, for example, at least 1×10 per milliliter of composition or at least 1×10 per CFU / g of composition. 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 or more CFU concentrations.
[0060] Advantageously, in preferred embodiments, the compositions of the present invention may alter the metabolic pathways of iron-trapping pathogens, resulting in reduced activity, virulence and / or pathogenicity.
[0061] In some embodiments, the composition can also be used to clean inert surfaces containing iron-trapping pathogens. Advantageously, in some embodiments, this can reduce the occurrence of infection caused by the pathogens.
[0062] In a preferred embodiment, the beneficial microorganisms of the composition of the present invention are non-pathogenic fungi, yeasts and / or bacteria that can collect iron naturally or by genetic modification. The beneficial microorganisms can be in active form, inactive form and / or dormant form. In a preferred embodiment, the microorganism is a microorganism described as "generally recognized as safe" by the relevant regulatory agency or GRAS.
[0063] In certain embodiments, these microorganisms are also capable of producing one or more of the following: surfactants, such as lipopeptides and / or glycolipids; bioactive substances with antimicrobial and immunomodulatory effects; polyketides; acids; peptides; anti-inflammatory compounds; enzymes, such as amylases, cellulases, proteases and / or lipases; and sources of amino acids, vitamins and other nutrients.
[0064] The microorganism of the present invention can be a natural microorganism or a genetically modified microorganism. For example, the microorganism can be transformed with a specific gene to show a specific characteristic. The microorganism can be a mutant of a desired strain. As used herein, "mutant" refers to a strain, genetic variant or subtype of a standard bacterium, wherein the mutant has one or more genetic variations (e.g., point mutation, missense mutation, nonsense mutation, deletion, duplication, frameshift mutation or amplification mutation) compared to the standard bacterium. The process of preparing mutants is well known in the field of microbiology. For example, UV mutagenesis and nitrosoguanidine are widely used for this purpose.
[0065] In some embodiments, beneficial microorganisms are selected based on natural or acquired resistance to certain antibiotics applied to an environment containing iron-trapping pathogens, e.g., to control pathogenic and / or harmful microorganisms in a living subject or elsewhere in the environment.
[0066] In one embodiment, the composition includes about 1×10 6 About 1×10 13 , about 1×10 7 About 1×10 12 , about 1×10 8 About 1×10 11 , or about 1×10 9 About 1×10 10 CFU / g of various types of microorganisms.
[0067] In one embodiment, the composition includes a total of about 0.001% to 100%, about 1% to 90%, or about 10% to 75% total microorganisms by volume.
[0068] In certain embodiments, the composition comprises growth byproducts of microorganisms, but does not comprise live microorganisms. For example, in certain embodiments, pathogenic microorganisms are only used to produce growth byproducts of the composition according to the present invention, rather than being directly applied to the environment.
[0069] The microorganisms may include yeast, bacteria and / or fungi, such as Acaulospora, Acidithiobacillus spp. (e.g., A.ferooxidans, A.albertensis, A.caldus, A.cuprithermicus, A.ferrianus, A.ferridurans, A.ferriphilus, A.ferrivorans, A.ferrooxidans, A.sulfuriphilus, and A.thiooxidans), Acremonium chrysogenum, Agrobacterium (e.g., A. radiobacter), Aspergillus, Aureobasidium (e.g., A. pullulans), Azospirillum (e.g., A. brasiliensis), Azotobacter (A. vinelandii, A. chroococcum), Bacillus (e.g., B. amyloliquefaciens, B. coagulans, B. firmus, B. laterosporus), orus, B. licheniformis, B. megaterium, B. mucilaginosus, B. subtilis), Blakeslea, Candida (e.g., C. albicans, C. apicola, C. batistae, C. bombicola, C. floricola, C. kuoi, C. riodocensis, C. nodaensis, C. stellate), Cryptococcus, Debaryomyces (e.g., D. hansenii, D.hansenii), Dipodascopsism, Entomophthora, Escherichia coli, Frateuria (e.g., F. aurantia), Hanseniaspora (e.g., H. uvarum), Hansenula, Issatchenkia, Kluyveromyces (e.g., K. phaffii), Lentinula spp. (e.g., L. edodes), Legionella pneumophila, Lipomyces, Magnetospirillum magneticum, Magnetococcus marinus, methanogens, Metschnikowia sp. (M. pulcherrimia), Meyerozyma (e.g., M. guilliermondii, M. caribbica), Monascus purpureus, Mortierella, Mucor (e.g., M. piriformis), Neisseria meningitidis, Pantoea (e.g., P. agglomerans, P. allii), Penicillium, Phythium, Phycomyces, Pichia (e.g., P. anomala, P. guilliermondii, P. occidentalis, P. kudriavzevii), Pleurotus erythrocytes, otus (e.g., P. ostreatus, P. ostreatus, P. sajorcaju, P. cystidiosus, P. cornucopiae, P. pulmonarius, P. tuberregium, P. citrinopileatus, and P. flabellatus), Pseudomonas (e.g., P. chlororaphis, P. aeruginosa, P.aeruginosa, Pseudomonas koreensis), Pseudozyma (e.g., P. aphidis, P. antarctica), Rhizobium radiobacter, Rhizopus, Rhodospirillum (e.g., R. rubrum), Rhodotorula (e.g., R. bogoriensis), Saccharomyces (e.g., Saccharomyces cerevisiae, S. boulardii, S. torula), Sphingomonas (e.g., S. pauc imobilis), Starmerella (e.g., S. bombicola), Streptomyces, Torulopsis, Thraustochytrium, Trichoderma (e.g., T. reesei, T. harzianum, T. viridae), Ustilago (e.g., U. maydis), Vibrio cholerae. cholerae, Wickerhamiella (e.g., W. domericqiae), Wickerhamomyces (e.g., W. anomalus), Williopsis (e.g., W. mrakii), Zygosaccharomyces (e.g., Z. bailii), and others (including those listed as pathogens elsewhere in this disclosure).
[0070] If present, the fungus may be in the form of living or non-living cells, mycelium, spores and / or fruiting bodies. The fruiting bodies (if present) may be, for example, chopped and / or mixed into granular and / or powdered form.
[0071] If present, the yeast may be in the form of live or inactivated cells or spores, and may also be in the form of dry cells and / or dormant cells (eg, yeast hydrolysate).
[0072] If present, the bacteria may be in the form of vegetative or planktonic cells, biofilms, spores, and / or dried cell or spore masses.
[0073] In some embodiments, dried microorganisms (eg, spores) may be mixed with fillers known in the art, such as, for example, microcrystalline cellulose (MCC).
[0074] In one embodiment, the composition comprises one or more Bacillus bacteria and / or growth byproducts thereof. In certain embodiments, the Bacillus is Bacillus amyloliquefaciens, Bacillus subtilis, Spore lactic acid bacteria and / or Bacillus licheniformis.
[0075] In one embodiment, the composition comprises Bacillus amyloliquefaciens NRRL B-67928 "B.amy" and / or its growth byproducts. Cultures of the Bacillus amyloliquefaciens "B.amy" microorganism have been deposited at the Northern Regional Research Laboratory (NRRL) Culture Collection of the Agricultural Research Service at 1815 N. University St., Peoria, IL, USA. The deposit has been assigned the accession number NRRL B-67928 and was deposited on February 26, 2020.
[0076] In one embodiment, the composition comprises a strain of Bacillus subtilis and / or its growth byproducts. In a specific embodiment, the strain is Bacillus subtilis B4 (NRRL B-68031). Cultures of the B4 microorganism have been deposited at the Northern Regional Research Laboratory (NRRL) Culture Collection of the Agricultural Research Service at 1815 North University St., Peoria, IL, USA. The deposit has been assigned a deposit number, NRRL B-68031, and was deposited on May 6, 2021.
[0077] B4 is a Gram-positive spore-forming strain of Bacillus subtilis capable of anaerobic growth (obligate anaerobe). The B4 strain is preferably administered as a spore, but germinates in an acidic environment where it can grow as a biofilm. Surprisingly, it was found that B4, when grown as a biofilm, produces one or more compounds that can gather, chelate or otherwise trap iron. In certain embodiments, the compound is pulcherrimone and / or pulcherrimone acid.
[0078] Advantageously, the microorganisms and / or exopolysaccharides (EPS) of the biofilm efficiently store freely available iron using an iron-capturing agent such as pulcherrimidine and / or pulcherrimidine acid when subjected to low pH values (e.g., less than 6.8, less than 5.0, or less than 4.8).
[0079] B4 has particular advantages over other traditional probiotic microorganisms when administered to a living subject because it is able to produce relatively large amounts of the lipopeptide surfactant (e.g., exceeding the amount of wild-type Bacillus subtilis), as well as digestive enzymes (including, for example, cellulases and amylases). These enzymes help break down nutrients into smaller units, such as volatile fatty acids (e.g., propionate, acetate, butyrate), glucose, and amino acids.
[0080] The proprietary cultures described herein have been deposited under conditions that ensure that they are available during the pendency of this patent application to persons whom the Director of the Patent and Trademark Office deems entitled to access them pursuant to 37 CFR 1.14 and 35 U.S.C. 122. Deposits of the present invention may be made available in accordance with the requirements of foreign patent laws in countries in which the counterpart of the present application or its progeny has been filed. It should be understood, however, that the provision of a deposit does not constitute a derogation from patent rights granted by governmental action, but rather constitutes a license to practice the present invention.
[0081] Furthermore, each of the deposited cultures of the present invention is maintained and made available to the public, in accordance with the provisions of the Budapest Treaty on the Deposit of Microorganisms, by all necessary means to preserve its viability and protect it from contamination, for a period of at least five years after the last request for samples of the deposit and, in any case, for at least 30 (thirty) years after the date of deposit or for the enforceability of any patent that may issue disclosing the culture. The depositor acknowledges that it is responsible for replacing the deposit if the depositor is unable to provide samples upon request due to the state of the deposit. Upon the grant of a patent disclosing a deposit of cultures of the present invention, all restrictions on making the culture available to the public are irrevocably lifted.
[0082] In certain embodiments, the composition may include other microorganisms that are capable of naturally producing or genetically engineering pulcherrimin and / or pulcherriminic acid, or other compounds that are capable of sequestering, chelating or otherwise trapping iron. In specific embodiments, the microorganism is capable of growing as a biofilm.
[0083] In certain embodiments, the microorganism is a naturally occurring microorganism or a transgenic microorganism capable of regulating genes involved in iron capture and transport, for example, HFE, GDF15, TWSG1, ERFE, matrix enzyme 2, TF, TFR1, TFR2, HAMP, and HJV.
[0084] In certain embodiments, the composition may comprise a crude or purified siderophore or plant siderophore, or other molecules with high iron affinity, for example, pulcherrimin, pulcherriminic acid, citrate, citric acid, EDTA (ethylenediaminetetraacetic acid), iron EDTA, DTPA (diethylenetriaminepentaacetic acid), EDDHA (ethylenediamine-di-o-hydroxyphenylacetic acid), N,N-dihydroxy-N,N′-diisopropyladipamide (DPH), 2,3-dihydroxybenzoic acid, azotocin, transferrin, enterobactin, purulent azotocin, protochelatin, chelatin, bacteriocin, vibriocin, vibrioferrin, azotocin, aminochelatin, yersin, agarobactin, grape agglutinin, ferrochrome, deferasirox, deferiprone, deferoxamine, fusarin, chrysin, achromatin, ornithine, rhodotorulic acid, lysine, glutamic acid, gluconic acid, ferric oxyhydroxide minerals, ferrihydrite, magnetite, hematite, goethite, siderocite, hydroxamate, catecholase, salicylate, carboxylate, mugineic acid, ferulic acid, caffeic acid and / or nicotinamide.
[0085] The composition may also include other microbial growth byproducts. The microbial growth byproducts may be produced by the microorganisms of the composition, and / or they may be produced separately, for example, by the microorganisms listed herein and added to the composition.
[0086] In certain embodiments, the composition may include residual substrates from the culture process and / or purified or unpurified growth byproducts, such as biosurfactants, killer factors, enzymes, polyketides, and / or other metabolites. The microorganism may be active or inactive, although in preferred embodiments, if the microorganism is considered a pathogen, the microorganism is inactivated and / or removed from the composition.
[0087] In one embodiment, the growth by-products are purified from the substratum producing the by-products. In addition, in one embodiment, the growth by-products are used in a crude form. The crude form may include, for example, a liquid supernatant generated by the microorganisms that culture the relevant growth by-products (comprising residual cells and / or nutrients).
[0088] Growth byproducts may include metabolites or other biochemicals produced as a result of cell growth, including, for example, amino acids, peptides, polyketides, antibiotics, proteins, enzymes, biosurfactants, solvents, vitamins, and / or other metabolites.
[0089] The microorganisms and / or growth byproducts present in the composition can be used to inhibit pathogens and / or biological pathways that contribute to their pathogenicity and / or virulence, disrupt pathogen biofilms, and / or reduce the accumulation of H2 in the environment of iron-trapping pathogens.
[0090] Additional components
[0091] In certain embodiments, the composition includes a germination enhancer for enhancing germination of spore-shaped microorganisms in a microbial-based composition. In a specific embodiment, the germination enhancer is an amino acid, such as, for example, L-alanine and / or L-leucine. In one embodiment, the germination enhancer is manganese.
[0092] In certain embodiments, the composition comprises an organic acid selected from the following: for example, acetic acid, citric acid, formic acid, lactic acid, malic acid, oxalic acid, tartaric acid, uric acid, propionic acid, butyric acid, sorbic acid, fumaric acid, benzoic acid, hydrofluoric acid, caproic acid, salicylic acid, gluconic acid, pyruvic acid, adipic acid, trichloroacetic acid, glycolic acid, cinnamic acid, carboxylic acid, succinic acid, carbonic acid, glutaric acid, capric acid and ascorbic acid. In some embodiments, the composition comprises an inorganic acid selected from the following: for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, boric acid, perchloric acid, hydrofluoric acid, hydrobromic acid and sulfonic acid. Preferably, the acid is present in an amount suitable for adjusting the pH value of the composition or the environment in which it is used to 6.8 or lower, preferably 5.0 or lower, more preferably 4.8 or lower.
[0093] In certain embodiments, the composition may include a chelating agent, which may be, but is not limited to, ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), phosphonates, succinic acid (DMSA), diethylenetriaminepentaacetic acid (DTPA), N-acetylcysteine, N-hydroxyethylethylenediaminetriacetic acid (HEDTA), organic acids with more than one coordinating group (e.g., erythromycin), STPP (sodium tripolyphosphate, Na5P3O 10 ), trisodium phosphate (TSP), water, carbohydrates, organic acids with one coordinating group (e.g., citric acid), lipids, steroids, amino acids or related compounds (e.g., glutathione), peptides, phosphates, nucleotides, tetrapyrroles, ferroamines, ionophores, or phenols, sodium citrate, sodium gluconate, ethylenediamine disuccinic acid (EDDS), iminodisuccinic acid (IDS), L-glutamic acid diacetic acid (GLDA), GLDA Na4, methylglycine diacetic acid (MGDA), polyaspartic acid (PASA), hemoglobin, chlorophyll, lipophilic β-diketone and (14,16)-heteronedione, ethylenediamine-N,N'-diglutaric acid (EDDG), ethylenediamine-N,N'-dimalonic acid (EDDM), 3-hydroxy-2,2-iminodisuccinic acid (HIDS), 2-hydroxyethyliminodiacetic acid (HEIDA), pyridine-2,6-dicarboxylic acid (PDA), trimethylglycine (TMG), titanium reagent, or any combination thereof.
[0094] In one embodiment, the composition includes one or more fatty acids. The fatty acids can be produced by the microorganisms of the composition, and / or produced separately and included as additional components. In certain preferred embodiments, the fatty acids are saturated long-chain fatty acids having a carbon backbone of 14 to 20 carbons, such as, for example, myristic acid, palmitic acid, or stearic acid. In some embodiments, a combination of two or more saturated long-chain fatty acids is included in the composition. In some embodiments, saturated long-chain fatty acids can inhibit methane production and / or increase cell membrane permeability of methanogens.
[0095] In certain embodiments, the composition comprises one or more enzymes that help break down food sources into smaller units, such as volatile fatty acids (e.g., propionate, acetate, butyrate), glucose, and amino acids. These enzymes can be produced by the microorganisms of the composition, and / or produced separately and included as additional components. Non-limiting examples of digestive enzymes include amylase, maltase, lactase, lipase, protease, sucrase, and cellulase.
[0096] In some embodiments, the composition may include additional components that are known to reduce methane, such as, for example, nitrates (e.g., calcium nitrate, ammonium nitrate, sodium nitrate, potassium nitrate, and magnesium nitrate); seaweed (e.g., Asparagus and / or Asparagus spinosa, etc.); macroalgae; nitrooxypropanols (e.g., 3-nitrooxypropanol and / or ethyl 3-nitrooxypropanol, etc.); anthraquinones; ionophores (e.g., monensin and / or lasalocid, etc.); Polyphenols (e.g., saponins, tannins, etc.); yucca extracts (e.g., steroidal saponin-producing plant species, etc.); Quillaja bark extracts (triterpenoid saponin-producing plant species); organosulfurs (e.g., garlic extracts, etc.); flavonoids (e.g., quercetin, rutin, kaempferol, naringin, and anthocyanins, etc.); bioflavonoids from green citrus fruits, rose hips, and / or red currants; carboxylic acids; and / or terpenes (e.g., d-limonene, pinene, and citrus extracts, etc.).
[0097] In one embodiment, the composition may include one or more biosurfactants. Biosurfactants are a group of structurally diverse surface-active substances produced by microorganisms that are biodegradable and can be efficiently produced by selected organisms on renewable substrates. All biosurfactants are amphiphilic molecules. Amphiphilic molecules consist of two parts: a polar (hydrophilic) group and a non-polar (hydrophobic) group. The lipophilic portion of the biosurfactant molecule is usually a hydrocarbon chain of a fatty acid, while the hydrophilic portion is formed by an ester or alcohol group of a neutral lipid, a carboxylate group of a fatty acid or an amino acid (or peptide), an organic acid in the case of flavonoids, or a carbohydrate in the case of glycolipids.
[0098] Biosurfactants, due to their amphiphilic structure, increase the surface area of hydrophobic insoluble substances, improve the water bioavailability of these substances, and change the properties of bacterial cell surfaces. Biosurfactants accumulate at interfaces, thereby reducing interfacial tension, resulting in the formation of aggregated micellar structures in solution. Safe and effective microbial biosurfactants reduce surface tension and interfacial tension between liquid, solid, and gas molecules. The ability of biosurfactants to form pores and destabilize biofilms allows biosurfactants to be used as antibacterial, antifungal, and hemolytic agents.
[0099] Advantageously, in certain embodiments, biosurfactants can help disrupt and / or penetrate biofilms to increase the effectiveness of antimicrobial compounds.
[0100] The biosurfactant according to the present invention may include, for example, glycolipids, lipopeptides, flavonoids, phospholipids, fatty acid esters, and high molecular weight polymers (such as lipoproteins, lipopolysaccharide-protein complexes, and polysaccharide-protein-fatty acid complexes, etc.).
[0101] In one embodiment, the biosurfactant is a glycolipid. Glycolipids may include, for example, sophorolipids, rhamnolipids, cellobiose lipids, mannoerythritol lipids, and trehalose lipids. In one embodiment, the biosurfactant is a lipopeptide. Lipopeptides may include, for example, surfactin, iturin, sphingomyelin, mucin, fengycin, and lichenin. In certain embodiments, a mixture of biosurfactants is used.
[0102] In one embodiment, the biosurfactant has been purified from a fermentation medium in which the biosurfactant was produced. Additionally, in one embodiment, the biosurfactant is used in a crude form (including a fermentation broth from a culture of a microorganism that produces the biosurfactant). The crude biosurfactant solution may include about 0.001% to 99%, about 25% to about 75%, about 30% to about 70%, about 35% to about 65%, about 40% to about 60%, about 45% to about 55%, or about 50% pure biosurfactant, as well as residual cells and / or nutrients.
[0103] In one embodiment, the composition includes 1 ml / L to 10 ml / L of saponin or 2 ml / L to 6 ml / L of rumen fluid. Saponin is a natural surfactant present in many plants and exhibits properties similar to microbial surfactants (e.g., self-binding and interacting with biofilms). Saponin has three basic categories: triterpenoid saponins, steroidal saponins, and steroidal glycoalkaloids.
[0104] Some well-known triterpenoid saponin plant families include Leguminosae, Amaranthaceae, Apiaceae, Caryophyllaceae, Aquifoliaceae, Araliaceae, Cucurbitaceae, Berberidaceae, Chenopodiaceae, Myrsinaceae, and Zygophyllaceae, etc. Quillaja sapodilla and legumes (such as soybeans, beans, and peas) are rich sources of triterpenoid saponins. Steroidal saponins are commonly found in members of the following families: Agavaceae, Alliaceae, Asparagaceae, Dioscoreaceae, Liliaceae, Amaryllidaceae, Bromeliaceae, Palmae, and Scrophulariaceae, and are abundantly accumulated in crop plants such as Dioscorea, Allium, Asparagus, Fenugreek, Yucca, and Ginseng. Steroidal glycoalkaloids are commonly found in plants of the Solanaceae family such as tomatoes, potatoes, eggplants, and peppers.
[0105] In one embodiment, the composition may include one or more biocidal compounds. The biocidal substance can be an antibiotic, including, for example, penicillins (such as penicillin G, penicillin V, ampicillin, amoxicillin, bacampicillin, carbenicillin, carbocycline, carbosacillin, ticarcillin, azlocillin, mezlocillin, methicillin, piperacillin, etc.), tetracyclines (such as chlortetracycline, oxytetracycline, metacycline, doxycycline, minocycline, etc.), cephalosporins (such as cefoperazone, cephalexin, cefoperadine, cephalothin, cefpirin, cefazolin, cefaclor, cefoperadine, cefoperoxydim, cefonicid, cefoxitin, cefotetan, cefuroxime axetil, cefmetazole, cefuroxime, loracarb, cefoperazone, cefoperazone, ceftriaxone, ceftazidime, cephalosporin, oxime, cefpodoxime, ceftibuten, etc.), fluoroquinolones (such as levofloxacin), quinolones (such as nelonic acid, cinoxacin, ciprofloxacin and norfloxacin, etc.), lincomycins (such as clindamycin), macrolides (such as erythromycin, azithromycin), sulfonones (such as dapsone), sulfonamides (such as sulfonamide, sulfadiazine, sulfamethoxazole, sulfisoxazole, sulfacetamide, sulfamethoxazole), lipopeptides (such as daptomycin), polypeptides (such as subtilisin), glycopeptides (such as vancomycin), aminoglycosides (such as streptomycin, gentamicin, tobramycin, amikacin, netilmicin, kanamycin, etc.), nitroimidazoles (such as metronidazole) and / or carbapenems (such as thanamycin), etc.
[0106] In some embodiments, the biocidal substance may include essential oils, plant extracts, or other plant extracts that have bactericidal and / or antimicrobial effects. These may include oils / extracts at concentrations between 1% and 10% v / v (extract / invention), such as Inula helenium, L. Asteraceae, Rose (Rosadamascena L., Rosaceae), Lavender (Lavandula angustifolia L., Labiatae), Chamomile (Matricaria recutica L., Asteraceae), Orange (Rutaceae), Grapefruit (Citrus paradisi), Eucalyptus (Eucalyptus globulus L., Myrtaceae), Geranium (Geranium robertianum L., Geraniaceae), Juniperus communis L., Cupressaceae), Citrus (Citrus sinensis L., Rutaceae), Tea Tree (Melaceuca alternifolia), Manuka (Leptospermum scoparium), neem (Azadirachtaindica, A.Juss), tea tree (Camellia sinensis), rosemary (Rosmarinus officinalis L., Lamiaceae), lemon, oregano, cinnamon, eucalyptus, citronella and thyme oil.
[0107] Other known antimicrobial agents (including non-therapeutic antimicrobial agents) may also be used, such as alcohols, aldehydes, chlorine and chlorine-releasing agents (e.g., sodium hypochlorite, chlorhexidine, chlorhexidine gluconate), iodine, peroxide compounds (e.g., hydrogen peroxide, peracetic acid), phenolic compounds, quaternary ammonium compounds (e.g., benzalkonium chloride), bases (e.g., sodium hydroxide, potassium hydroxide, sodium carbonate), and acids (e.g., mineral acids and organic acids).
[0108] In one embodiment, the compositions of the invention may include additional nutrients that supplement the diet of an animal and / or promote the health and / or well-being of an animal, such as, for example, sources of amino acids (including essential amino acids), peptides, proteins, vitamins, trace elements, fats, fatty acids, lipids, carbohydrates, sterols, enzymes, prebiotics, and minerals. In some embodiments, the microorganisms of the composition produce and / or provide these substances.
[0109] In one embodiment, the composition of the present invention may include one or more additional substances and / or nutrients to supplement the needs of the beneficial microorganisms of the composition and / or the needs of the human, animal or plant to which the supplementary composition is applied. These may include, for example, sources of amino acids (including essential amino acids), peptides, proteins, vitamins, trace elements, fats, fatty acids, lipids, carbohydrates, sterols, enzymes and minerals (such as calcium, magnesium, phosphorus, potassium, sodium, chlorine, sulfur, chromium, cobalt, copper, iodine, iron, manganese, molybdenum, nickel, selenium and zinc). In some embodiments, the microorganisms of the composition generate and / or provide these substances.
[0110] Preferred compositions include any combination of vitamins and / or minerals. The vitamins used in the compositions of the present invention may include, for example, vitamin A, vitamin E, vitamin K3, vitamin D3, vitamin B1, vitamin B3, vitamin B6, vitamin B12, biotin, folic acid, pantothenic acid, nicotinic acid, choline chloride, inositol, and para-aminobenzoic acid. Minerals may include, for example, calcium, magnesium, phosphorus, potassium, sodium, chlorine, sulfur, chromium, cobalt, copper, iodine, iron, manganese, molybdenum, nickel, selenium, and zinc. Other components may include, but are not limited to, antioxidants, beta-glucans, bile salts, cholesterol, enzymes, carotenoids, and many other ingredients. Typical vitamins and minerals are, for example, vitamins and minerals that are recommended for daily intake and meet the recommended daily intake (RDA), although specific intake may be different.
[0111] In certain embodiments, the composition may further comprise one or more carriers and / or excipients suitable for internal or external delivery of the composition to a human or animal subject, a plant, or an inert surface.
[0112] Carriers and / or excipients according to the present invention may include any and all solvents, diluents, buffers (such as, for example, neutral buffered saline, phosphate buffered saline or optionally Tris-HCl, acetate or phosphate buffers), oil-in-water or water-in-oil emulsions, aqueous compositions with or without organic co-solvents suitable for, e.g., IV use, solubilizers (such as, for example, Tween 80, polysorbate 80), colloids, dispersion media, carriers, fillers (e.g., MCC), chelating agents (such as, for example, EDTA or glutathione), amino acids (such as, for example, glycine), proteins, disintegrants, binders, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, fragrances, thickeners, coatings, preservatives (such as, for example, thimerosal, benzyl alcohol), antioxidants (such as, for example, ascorbic acid, sodium metabisulfite), tonicity control agents, absorption delaying agents, adjuvants, bulking agents (such as, for example, lactose, mannitol), etc. The use of carriers and / or excipients in the fields of pharmaceuticals and supplements, agricultural and cleaning compositions is well known. Except insofar as any conventional media or agent is incompatible with a component of the present compositions, its use in the present compositions is contemplated.
[0113] In certain embodiments, the compositions comprise a filler, such as microcrystalline cellulose (MCC).
[0114] In certain embodiments, the composition may include glucose (eg, in the form of molasses), glycerol, and / or glycerol as an osmotic pressure substance or as a supplement to an osmotic pressure substance to increase the osmotic pressure during storage and transportation of the dry product.
[0115] The compositions can be formulated into preparations in solid, semisolid, liquid or gaseous forms, such as tablets, capsules, powder tablets, powders, granules, ointments, gels, emulsions, solutions, suppositories, drops, patches, injections, inhalants, aerosols, orally consumable food and beverage products, suspensions, concentrates, and other preparations suitable for a particular application.
[0116] In one embodiment, the composition can be formulated as a solution or suspension for administration via injection, for example. The solution or suspension may include a suitable nontoxic, parenterally acceptable diluent or solvent (such as mannitol, 1,3-butylene glycol, water, Ringer's solution, or isotonic sodium chloride solution), or a suitable dispersant or wetting agent and suspending agent (such as sterile, non-irritating, fixed oils, including synthetic monoglycerides or diglycerides), and fatty acids (including oleic acid). An illustrative example of a carrier for intravenous use includes a mixture of 10% USP ethanol, 40% USP propylene glycol or polyethylene glycol 600 and the balance USP water for injection (WFI). Other exemplary carriers for intravenous use include 10% USP ethanol and USP WFI; 0.01% 0.1% triethanolamine in USP WFI; or 0.01% to 0.2% dipalmitoylphosphatidylcholine in USP WFI; and 1% to 10% squalene or parenteral vegetable oil-in-water emulsions. Water or saline solutions and liquid aqueous glucose and glycerol solutions can be preferably used as carriers, particularly for injectable solutions. Illustrative examples of carriers for subcutaneous or intramuscular use include phosphate buffered saline (PBS) solution, 5% dextrose in WFI and 0.01% to 0.1% triethanolamine in 5% dextrose or 0.9% sodium chloride in USP WFI, or a 1:2 or 1:4 mixture of 10% USP ethanol, 40% propylene glycol, and the balance an acceptable isotonic solution (such as 5% dextrose or 0.9% sodium chloride); or 0.01% to 0.2% dipalmitoylphosphatidylcholine and 1% to 10% squalene in USP WFI or a parenteral vegetable oil-in-water emulsion.
[0117] In one embodiment, the composition can be made into an aerosol formulation, so that it can be atomized or inhaled, for example. Suitable formulations used in aerosol or spray form are powders, particles, solutions, suspensions or emulsions, etc. The preparations used for oral or nasal aerosol or inhalation can also be prepared using carriers, including for example saline, polyethylene glycol or glycols, DPPC, methylcellulose, or with a mixture of powder dispersants or fluorocarbons. Aerosol formulations can be put into pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen, fluorocarbons and / or other solubilizing agents or dispersants known in the art. Exemplarily, delivery can be realized by using any other device in disposable delivery devices, sprayers, breath-activated powder inhalers, aerosol metered-dose inhalers (MDI) or the available numerous sprayer delivery devices in this area. Additionally, spray tents can also be used or directly applied by endotracheal tubes.
[0118] In one embodiment, the composition can be formulated to be applied topically to the skin, for example as a topical composition, including rinses, sprays or drops, emulsions, gels, ointments, creams, foams, powders, solids, sponges, tapes, steam, pastes, tinctures, or using transdermal patches. In addition to any pharmaceutically active carrier, suitable formulations for topical application may also include, for example, emollients such as carnava wax, cetyl alcohol, cetyl ester wax, emulsifying wax, aqueous lanolin, lanolin, lanolin alcohol, microcrystalline wax, paraffin, petrolatum, polyethylene glycol, stearic acid, stearyl alcohol, white beeswax or yellow beeswax. Additionally, the composition may contain a humectant such as glycerol, propylene glycol, polyethylene glycol, sorbitol solution and 1,2,6-hexanetriol, or a penetration enhancer such as ethanol, isopropanol or oleic acid.
[0119] In one embodiment, the composition can be formulated for direct administration to the digestive system of a human or animal subject via, for example, injection and / or endoscopy as a solution or suspension, etc. The solution or suspension may include a suitable nontoxic, enterally acceptable diluent or solvent (such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution), or a suitable dispersant or wetting agent and suspending agent (such as including synthetic monoglycerides or diglycerides, etc.), sterile, bland, fixed oils, and fatty acids (including oleic acid). Water or saline solutions and liquid glucose and glycerol aqueous solutions may be preferably used as carriers, particularly for solutions for enteral injection.
[0120] In an exemplary embodiment, the composition based on microorganism can be configured to be administered orally via oral consumables. Oral consumables according to the present invention are any preparations or compositions suitable for consumption, nutrition, oral hygiene or pleasure, and are intended to be introduced into the human or animal oral cavity and stay for a period of time, then swallow (for example, ready-to-eat food or pill) or take out (for example, chewing gum or oral hygiene or medical mouthwash product) from the oral cavity again. Although oral deliverable drugs can be configured to oral consumables, and oral consumables can include oral deliverable drugs, these two terms are not meant to be interchangeable in this article.
[0121] Orally consumable products include all substances or products intended for ingestion by humans or animals in a processed, semi-processed or unprocessed state. This also includes substances that are added to orally consumable products (especially foods and drugs) during their production, treatment or processing and are intended to be introduced into the oral cavity of humans or animals.
[0122] Oral consumables may also include substances intended to be ingested by humans or animals and then digested in an unmodified, prepared or processed state. Thus, oral consumables according to the present invention may also include an enteric casing, coating or other packaging intended to be swallowed or expected to be swallowed with the product.
[0123] In one embodiment, the oral consumable is a capsule, pill, syrup, emulsion or liquid suspension containing a desired oral deliverable substance. In one embodiment, the oral consumable may include an oral deliverable substance in powder form that can be mixed with water or another liquid to produce a drinkable oral consumable.
[0124] In some embodiments, the oral consumables according to the present invention may include one or more preparations for nutrition or pleasure. These include in particular baked products (e.g., bread, dry biscuits, cakes and other pastries), candies (e.g., chocolate, chocolate bar products, other bar products, pectin, coated tablets, hard caramels, toffee and caramel, and chewing gum), alcoholic or non-alcoholic beverages (e.g., cocoa, coffee, green tea, black tea, black tea or green tea beverages enriched with green tea or black tea extracts, red date tea, other herbal teas, fruit-containing lemonades, isotonic beverages, soft drinks, nectar, fruit and vegetable juices, and fruit or vegetable juice preparations), Instant beverages (e.g. instant cocoa drinks, instant tea drinks and instant coffee drinks), meat products (e.g. ham, fresh or raw sausage preparations, and seasoned or cured fresh or bacon products), eggs or egg products (e.g. dried whole eggs, egg whites and egg yolks), cereal products (e.g. breakfast cereals, cereal bars and precooked instant rice products), dairy products (e.g. full-fat, reduced-fat or fat-free milk drinks, rice pudding, yogurt, kefir, cream cheese, soft cheese, hard cheese, milk powder, whey, butter, buttermilk and partially or completely hydrolyzed products containing milk protein), soy protein or other soy fraction products (such as soy milk and products prepared therefrom, beverages containing isolated or enzyme-treated soy protein, beverages containing soy flour, soy lecithin-containing products, fermented products such as tofu or tempeh, and mixtures with fruit preparations and optional flavoring substances), fruit preparations (such as jam, fruit ice cream, fruit sauce and fruit fillings), vegetable preparations (such as ketchup, sauces, dried vegetables, deep-frozen vegetables, pre-cooked vegetables and cooked vegetables), snack products (such as baked or fried potato chips (potato chips) or potato dough products and corn- or peanut-based extrudates), products based on fats and oils or their emulsions (such as mayonnaise, flavored mayonnaise and condiments), other ready-to-eat meals and ready-to-eat soups (such as dry soups, instant soups and pre-cooked soups), seasonings (such as hand-sprinkled seasonings), sweetener compositions (such as sweetener tablets, sweetener powders and other preparations for sweetening or whitening beverages or other foods). The composition of the invention can also be used as a semi-finished product for the production of other compositions for nutrition or pleasure.
[0125] In certain embodiments, the composition is formulated for application to soil, seeds, whole plants, or plant parts (including but not limited to roots, tubers, stems, stalks, buds, flowers, and leaves). In certain embodiments, the composition is formulated as, for example, a liquid, powder, granule, microparticle, pellet, wettable powder, flowable powder, emulsion, microcapsule, oil, or aerosol.
[0126] In order to improve or stabilize the effect of the composition, it can be mixed with a suitable adjuvant and then used directly or diluted (if necessary). In a preferred embodiment, the composition is formulated into a liquid, a concentrated liquid or a dry powder or granules, which can be mixed with water and other components to form a liquid product.
[0127] Other components may be added to the composition, such as buffers, carriers, viscosity modifiers, preservatives, tracers, antimicrobials, other microorganisms, other microbial-based compositions, surfactants, emulsifiers, lubricants, solubility modifiers, pH modifiers, preservatives, stabilizers, UV inhibitors, essential oils, plant extracts, cross-linking agents, chelating agents, fatty acids, alcohols, reducing agents, synthetics, enzymes, dyes, colorants, fragrances, antimicrobial compounds, antibiotics, foaming agents, foam reducers, polymers, thickeners and chelating agents.
[0128] Exemplary embodiments
[0129] In some embodiments, the compositions of the present invention comprise the following:
[0130] A) one or more microorganisms (yeast, fungi and / or bacteria) capable of capturing iron and / or producing iron capturing growth byproducts, wherein preferably at least one of the one or more microorganisms is of the genus Bacillus, and wherein even more preferably the Bacillus is Bacillus subtilis NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928;
[0131] B) Iron-capturing substances selected from the group consisting of pulcherrimone, pulcherrimone acid, citrate, citric acid, EDTA (ethylenediaminetetraacetic acid), iron EDTA, DTPA (diethylenetriaminepentaacetic acid), EDDHA (ethylenediamine-di-o-hydroxyphenylacetic acid), N,N-dihydroxy-N,N′-diisopropylhexanediamine (DPH), 2,3-dihydroxybenzoic acid, azotocin, ferrochrome, deferasirox, deferiprone, deferoxamine, fusarin, chrysin, achromatin, ornithine , rhodotorulin, lysine, glutamic acid, gluconic acid, iron oxyhydroxide minerals, ferrihydrite, magnetite, hematite, goethite, siderite, transferrin, enterobactin, bacteriocin, vibriocin, azotocin, aminochelatin, pyocyanin, yersinic acid, agarobactin, grape agglutinin, hydroxamic acid, catecholase, salicylate, carboxylate, mugineic acid, ferulic acid, caffeic acid, enterobactin, pyocyanin, protochelatin, chelatin, vibrioferrin and / or nicotinamide.
[0132] C) carriers / excipients, which include solvents, diluents, buffers (such as, for example, neutral buffered saline, phosphate buffered saline or optionally Tris-HCl, acetate or phosphate buffer), oil-in-water or water-in-oil emulsions, aqueous compositions with or without organic co-solvents, solubilizers (such as, for example, Tween 80, polysorbate 80), colloids, dispersion media, carriers and / or fillers (e.g., MCC);
[0133] D) one or more acids selected from the group consisting of, for example, acetic acid, citric acid, formic acid, lactic acid, malic acid, oxalic acid, tartaric acid, uric acid, propionic acid, butyric acid, sorbic acid, fumaric acid, benzoic acid, hydrofluoric acid, caproic acid, salicylic acid, gluconic acid, pyruvic acid, adipic acid, trichloroacetic acid, glycolic acid, cinnamic acid, carboxylic acid, succinic acid, carbonic acid, glutaric acid, capric acid, ascorbic acid, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, boric acid, perchloric acid, hydrofluoric acid, hydrobromic acid and sulfonic acid in an amount suitable for adjusting the pH of the composition or its application environment to 6.8 or lower, preferably 5.0 or lower, more preferably 4.8 or lower; and / or
[0134] E) a biosurfactant selected from the group consisting of sophorolipids, rhamnolipids, cellobiose lipids, mannoerythritol lipids, trehalose lipids, surfactins, iturin, sphingomyelin, mucin, fengycin and lichenin; and / or
[0135] F) Biocidal compounds, such as antibiotics, biosurfactants or plant extracts.
[0136] In some embodiments, the composition comprises each of Component A to Component F. In some embodiments, the composition comprises any combination of Component A to Component F, or comprises any one of Component A to Component F alone.
[0137] In some embodiments, the composition comprises Bacillus subtilis NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928 in spore form, plant form, and / or biofilm form; and pulcherrimin and / or pulcherriminic acid.
[0138] In some embodiments, the composition comprises Bacillus subtilis NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928 in spore form, plant form, and / or biofilm form; and a carrier / excipient.
[0139] In some embodiments, the composition comprises Bacillus subtilis NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928 in spore form, plant form and / or biofilm form; and one or more acids listed in point D).
[0140] In some embodiments, the composition comprises Bacillus subtilis NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928 in spore form, plant form, and / or biofilm form; pulcherrimin and / or pulcherriminic acid; and a carrier / excipient.
[0141] In some embodiments, the composition comprises Bacillus subtilis NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928 in spore form, plant form and / or biofilm form; pulcherrimin and / or pulcherriminic acid; a carrier; and one or more acids listed in point D).
[0142] In some embodiments, the composition comprises Bacillus subtilis NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928 in spore form, plant form, and / or biofilm form; pulcherrimin and / or pulcherriminic acid; a carrier; and a biosurfactant.
[0143] In some embodiments, the composition comprises Bacillus subtilis NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928 in spore form, plant form, and / or biofilm form; pulcherrimin and / or pulcherriminic acid; a carrier; and a biocidal compound.
[0144] Production of microorganisms and / or microbial growth by-products
[0145] The present invention utilizes methods for the cultivation of microorganisms and the generation of microbial metabolites and / or other byproducts of microbial growth. The present invention further utilizes culture methods suitable for cultivating microorganisms and generating microbial metabolites at a desired scale. These culture processes include, but are not limited to, liquid culture / fermentation, solid state fermentation (SSF) and modifications, hybrids and / or combinations thereof.
[0146] As used herein, "fermentation" refers to the cultivation or growth of cells under controlled conditions. Growth can be aerobic or anaerobic. In a preferred embodiment, the microorganisms are grown using SSF and / or a modified form thereof.
[0147] In one embodiment, the invention provides materials and methods for generating biomass (eg, living cellular material), extracellular metabolites, residual nutrients, and / or intracellular components.
[0148] The microbial growth vessel used according to the present invention can be any fermenter or culture reactor for industrial use. In one embodiment, the vessel can have functional controls / sensors or can be connected to functional controls / sensors to measure important factors in the culture process, such as pH, oxygen, pressure, temperature, humidity, microbial density and / or metabolite concentration, etc.
[0149] In another embodiment, the vessel can also monitor the growth of microorganisms in the vessel (e.g., measuring cell number and growth stage). Additionally, daily samples can be taken from the vessel and counted by techniques known in the art (such as dilution plate techniques).
[0150] In one embodiment, the method comprises supplementing the culture with a nitrogen source. The nitrogen source can be, for example, potassium nitrate, ammonium nitrate, ammonium sulfate, ammonium phosphate, ammonia, urea, and / or ammonium chloride. These nitrogen sources can be used alone or in combination of two or more.
[0151] This method can provide oxygenation for the growing culture. One embodiment utilizes the slow movement of air to remove air with low oxygen content and introduce oxygenated air. In the case of submerged fermentation, the oxygenated air can be ambient air supplemented daily by mechanical means including an impeller for mechanically agitating the liquid and an air distributor for supplying gas bubbles to the liquid to dissolve oxygen into the liquid.
[0152] The method may further include supplementing the culture with a carbon source. The carbon source is typically a carbohydrate such as glucose, sucrose, lactose, fructose, trehalose, mannose, mannitol and / or maltose; an organic acid such as acetic acid, fumaric acid, citric acid, propionic acid, malic acid, malonic acid and / or pyruvic acid; an alcohol such as ethanol, propanol, butanol, amyl alcohol, hexanol, isobutanol and / or glycerol; and a fat and oil such as soybean oil, rapeseed oil, rice bran oil, olive oil, corn oil, sesame oil and / or linseed oil. These carbon sources may be used alone or in combination of two or more.
[0153] In one embodiment, the growth factors and micronutrients of microorganisms are included in the culture medium. When the growing microorganisms cannot generate all the vitamins they need, this is particularly preferred. Inorganic nutrients may also be included in the culture medium, which include trace elements such as iron, zinc, copper, manganese, molybdenum and / or cobalt. In addition, the source of vitamins, essential amino acids and trace elements may be included in the culture medium in the form of fine powder or meal (for example, corn flour) or in the form of extracts (such as yeast extract, potato extract, beef extract, soybean extract, banana peel extract, etc.) or in purified form. Amino acids (such as amino acids that can be used for protein biosynthesis) may also be included.
[0154] In one embodiment, the culture medium may also include an inorganic salt. Available inorganic salts may be potassium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate, magnesium chloride, iron sulfate, iron chloride, manganese sulfate, manganese chloride, zinc sulfate, lead chloride, copper sulfate, calcium chloride, sodium chloride, calcium carbonate and / or sodium carbonate. These inorganic salts may be used alone or in combination of two or more.
[0155] In one embodiment, one or more biostimulants, meaning substances that enhance the growth rate of microorganisms, may also be included. Biostimulants may be species specific and may enhance the growth rate of various species.
[0156] In some embodiments, the method for culturing may further include adding an antimicrobial agent to the culture medium before and / or during the culturing process.
[0157] In certain embodiments, antibiotics can be added to the culture at low concentrations to generate microorganisms that are resistant to antibiotics. Microorganisms that survive contact with the antibiotics are selected and repeatedly re-cultured with increasing antibiotic concentrations to obtain cultures that are resistant to antibiotics. This can be done in a laboratory setting or on an industrial scale using methods known in the art of microbiology. In certain embodiments, for example, the amount of antibiotic in the culture starts at 0.0001 ppm and increases by about 0.001 ppm to 0.1 ppm each iteration until the concentration in the culture is equal to or approximately equal to the dose typically applied to iron-trapped pathogens.
[0158] The pH of the mixture should be appropriate for the microorganism of interest. Buffers and pH adjusters (such as carbonates and phosphates) can be used to stabilize the pH near the preferred value. When metal ions are present in high concentrations, it may be necessary to use chelating agents in the culture medium.
[0159] The microorganisms can grow in a planktonic form or in a biofilm. If a biofilm is present, the vessel can contain a substrate on which the microorganisms can grow in a biofilm state. The system can also have the ability to apply stimuli (such as shear stress) that encourage and / or improve the growth characteristics of the biofilm.
[0160] In one embodiment, the culture method of the microorganism is carried out at about 5° to about 100° C., preferably 15° C. to 60° C., more preferably 25° C. to 50° C. In another embodiment, the culture can be carried out continuously at a constant temperature. In another embodiment, the culture may be subjected to temperature changes.
[0161] In one embodiment, the equipment used in the method and the culture process is a sterile device. Culture equipment (such as a reactor / vessel) can be separated from a sterilizing device (for example, an autoclave), but is connected thereto. Culture equipment can also have a sterilizing device that sterilizes on the spot before starting inoculation. Air can be sterilized by methods known in the art. For example, ambient air can pass through at least one filter before being introduced into the vessel. In other embodiments, the culture medium can be pasteurized, or alternatively not heated at all, but can utilize low water activity and low pH value to control the growth of undesirable bacteria.
[0162] In one embodiment, the present invention further provides a method for producing microbial metabolites by culturing the microbial strain of the present invention under conditions suitable for growth and metabolite production, and optionally purifying the metabolites, such as, for example, biosurfactants, enzymes, proteins, ethanol, lactic acid, β-glucans, peptides, metabolic intermediates, polyunsaturated fatty acids and lipids. The metabolite content generated by the method can be, for example, at least 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%.
[0163] The biomass content of the fermentation medium may be, for example, 5 g / l to 180 g / l or more, or 10 g / l to 150 g / l, etc. The cell concentration may be, for example, at least 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 or 1×10 13 cells.
[0164] Microbial growth byproducts produced by the microorganism of interest can be retained in the microorganism or secreted into the growth medium. The medium can contain compounds that stabilize the activity of the microbial growth byproducts.
[0165] The methods and apparatus for culturing microorganisms and producing microbial byproducts can be performed in a batch process, a quasi-continuous process, or a continuous process.
[0166] In one embodiment, all of the microbial culture composition is removed when the culture is complete (eg, when a desired cell density or density of a particular metabolite is reached). In this batch process, a completely new batch is started when the first batch is harvested.
[0167] In another embodiment, only a portion of the fermentation product is removed at any one time. In this embodiment, the biomass with living cells, spores, conidia, hyphae and / or mycelium remains in the vessel as an inoculant for a new culture batch. The removed composition can be a cell-free culture medium or contain cells, spores or other reproductive propagules and / or combinations thereof. A quasi-continuous system is created in this way.
[0168] Advantageously, the method does not require complex equipment or high energy consumption. The microorganisms of interest can be cultured and used on-site on a small or large scale, even while still mixed with their culture medium.
[0169] Preparation of microbial-based products
[0170] "Microbial-based products" are products that are applied in practice to achieve a desired effect. Microbial-based products can be simply microbial-based compositions obtained from a microbial culture process. In addition, microbial-based products may include further ingredients that have been added. These additional ingredients may include, for example, stabilizers, buffers, carriers (e.g., water or saline), nutrients that support further microbial growth addition, non-nutrient growth enhancers and / or agents that help track microorganisms and / or compositions in their application environment. Microbial-based products may also include mixtures based on microbial compositions. Microbial-based products may also include one or more components based on microbial compositions that have been treated in some manner, such as but not limited to filtration, centrifugation, lysis, drying, purification, etc.
[0171] A microbial-based product of the present invention is simply a fermentation medium containing the microorganism and / or microbial metabolites and / or any residual nutrients produced by the microorganism. The fermented product can be used directly without extraction or purification. If necessary, extraction and purification can be easily achieved using standard extraction and / or purification methods or techniques described in the literature.
[0172] The microorganisms in the microbial products can be in active or inactivated form. In addition, the microorganisms and the residual culture used can be removed from the composition. The microbial products can be used without further stabilization, preservation and storage. Advantageously, the direct use of these microbial products maintains the high vitality of the microorganisms, reduces the possibility of contamination by foreign agents and undesirable microorganisms, and maintains the activity of the by-products of microbial growth.
[0173] The microorganisms and / or culture medium (eg, fermentation broth or solid matrix) produced by the growth of the microorganisms can be removed from the growth vessel and transferred via tubing or the like for immediate use.
[0174] In one embodiment, the microbial-based product is the only microbial growth byproduct.For example, a biosurfactant produced by a microorganism can be collected from a liquid fermentation tank in a crude form that includes about 50% pure biosurfactant in the liquid fermentation broth.
[0175] In other embodiments, the microbial-based product (microorganism, culture medium, or microorganism and culture medium) can be placed in a container of appropriate size, taking into account, for example, the intended use, the intended method of use, the size of the fermenter, and any mode of transportation from the microbial growth facility to the point of use. Thus, the container in which the microbial-based composition is placed can be, for example, 1 gallon to 1,000 gallons or larger. In other embodiments, the container is 2 gallons, 5 gallons, 25 gallons or larger.
[0176] For example, when the yeast fermentation product is harvested from the growth vessel, when the obtained product is placed in a container and / or piped (or otherwise transported for use), other components may be added. Additives may be, for example, buffers, carriers, other microbial-based compositions produced in the same or different facilities, viscosity modifiers, preservatives, nutrients for microbial growth, tracers, solvents, antimicrobial agents, other microorganisms, and other ingredients specific to the intended use.
[0177] Other suitable additives that may be included in the formulations according to the invention include substances commonly used in such preparations. Examples of such additives include surfactants, emulsifiers, lubricants, buffers, solubility regulators, pH regulators, preservatives, stabilizers and UV inhibitors.
[0178] In one embodiment, the product may also include a buffer comprising an organic acid and an amino acid or its salt. Suitable buffers include citrate, gluconate, tartrate, malate, acetate, lactate, oxalate, aspartate, malonate, glucoheptonate, pyruvate, galactate, gluconate, propanol glycolate, glutamate, glycine, lysine, glutamine, methionine, cysteine, arginine, and mixtures thereof. Phosphoric acid and phosphorous acid, or their salts may also be used. Synthetic buffers may be used, but preferably natural buffers may be used, such as the organic acids and amino acids listed above, or their salts.
[0179] In another embodiment, the pH adjuster comprises potassium hydroxide, ammonium hydroxide, potassium carbonate or bicarbonate, hydrochloric acid, nitric acid, sulfuric acid, or a mixture.
[0180] In one embodiment, additional components may be included in the formulation, such as an aqueous solution formulation of a salt (such as sodium bicarbonate or carbonate, sodium sulfate, sodium phosphate, sodium hydrogen phosphate).
[0181] Advantageously, according to the present invention, microbial-based products may include fermentation broth in which the microorganisms are grown. The product may be, for example, at least 1%, 5%, 10%, 25%, 50%, 75% or 100% fermentation broth by weight. The biomass in the product may be, for example, 0% to 100% (including all percentages between 0% and 100%) by weight.
[0182] Alternatively, the product may be stored prior to use. The storage time is preferably short. Thus, the storage time may be less than 60 days, 45 days, 30 days, 20 days, 15 days, 10 days, 7 days, 5 days, 3 days, 2 days, 1 day or 12 hours. In a preferred embodiment, if living cells are present in the product, the product is stored at a cool temperature, such as, for example, below 20° C., 15° C., 10° C. or 5° C. On the other hand, the biosurfactant composition can generally be stored at ambient temperature.
[0183] Methods for inhibiting iron-trapping pathogens
[0184] In a preferred embodiment, the present invention provides methods for controlling iron-trapping pathogens, wherein a composition comprising an iron-trapping component is introduced into an environment where pathological microorganisms grow. Thus, the present invention provides methods for controlling pathogens, wherein a composition applied to the environment of a pathogen competes with the pathogen for iron resources. These methods can be used in environments including, for example, human and / or animal subjects, soil, plants, water and / or inanimate surfaces.
[0185] Advantageously, in certain embodiments, these methods result in the capture of iron present in the pathogen's environment, thereby inhibiting its pathogenicity via iron limitation. Thus, in preferred embodiments, these methods result in direct inhibition of the pathogen, increased competition for the pathogen by beneficial microorganisms, disruption of pathogenic biofilms, and / or disruption of one or more biological pathways by which the pathogen utilizes iron for growth, reproduction, and / or virulence.
[0186] Non-limiting examples of bacterial pathogens that can utilize one or more iron acquisition systems to enhance virulence of infection include: Escherichia spp. (e.g., Escherichia coli), Vibrio spp. (e.g., Vibrio cholerae, Vibrio vulnificus), Shigella spp. (e.g., Shigella flexneri, Shigella dysenteriae), Salmonella spp. (e.g., Salmonella enterica), Streptococcus spp. (e.g., Streptococcus pyogenes, Streptococcus agalactiae, Group A Streptococcus), Yersinia spp. (e.g., Yersinia pestis), Haemophilus spp. (e.g., Haemophilus influenzae H.influenzae), Klebsiella spp. (e.g., Klebsiella pneumoniae K.pneumoniae), Staphylococcus spp. (e.g., Staphylococcus aureus S.aureus), Mycobacterium spp. (e.g., Mycobacterium tuberculosis M.uberculosis), Neisseria spp. (e.g., Neisseria meningitidis N.meningitidis, Neisseria gonorrhoeae N.gonorrhoeae), Bartonella spp. (e.g., Bartonella quintana B.quintana), Bacillus spp. (e.g., Bacillus anthracis B.anthracis, Bacillus cereus), Serratia spp. (e.g., Serratia marcescens S.marcescens), Pseudomonas spp. (e.g., Pseudomonas aeruginosa P.aeruginosa), Legionella spp. (e.g., Legionella pneumophila L.pneumophila), Meningococcus spp.), Brucella spp. (e.g., Brucella abortus B.abortus), Listeria spp. (e.g., Listeria monocytogenes L.monocytogenes), Acinetobacter spp. (e.g., Acinetobacter baumannii A.baumannii), Francisella spp.(e.g. Francisella tularensis) and / or Haemophilus spp. (e.g. Haemophilus influenzae).
[0187] In some embodiments, the method comprises applying the iron trapping component according to the present invention together with an acid, wherein the acid adjusts the pH of the composition or environment to 6.8 or less, preferably 5.0 or less, and more preferably 4.8 or less. The acid may be an organic acid selected from the following items: for example, acetic acid, citric acid, formic acid, lactic acid, malic acid, oxalic acid, tartaric acid, uric acid, propionic acid, butyric acid, sorbic acid, fumaric acid, benzoic acid, hydrofluoric acid, caproic acid, salicylic acid, gluconic acid, pyruvic acid, adipic acid, trichloroacetic acid, glycolic acid, cinnamic acid, carboxylic acid, succinic acid, carbonic acid, glutaric acid, capric acid, and ascorbic acid. The acid may also be an inorganic acid selected from the following items: for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, boric acid, perchloric acid, hydrofluoric acid, hydrobromic acid, and sulfonic acid.
[0188] In certain embodiments, the methods comprise administering a composition according to the invention to a human or animal subject in need thereof (ie, a subject infected with or at risk of infection with an iron-trapping pathogen).
[0189] Administration to human or animal subjects can be acute or chronic (e.g., hourly, daily, weekly, monthly, etc.), and can also be used in combination with other drugs. The compositions of the present invention can be administered by any route of administration, as long as they are formulated for such a route. Thus, the therapeutic effects that can be achieved by the methods and compositions of the present invention can be, for example, systemic, local, tissue-specific, etc., depending on the specific needs of a given application of the present invention.
[0190] In one embodiment, the composition is administered orally, via injection (including intravenous, intraperitoneal, intramuscular, intrathecal or subcutaneous), via the skin (e.g., via a patch or directly on the skin for local or systemic effect), sublingually, buccally, rectally or vaginally. In addition, the composition can be sprayed into the nose, absorbed through the nasal membrane, atomized, inhaled through the mouth or nose, or applied in the eyes or ears.
[0191] In some embodiments, the method may also include applying materials to enhance the growth of the microorganisms of the composition of the present invention when applied (e.g., adding nutrients and / or prebiotics). In one embodiment, the nutrient source may include a source of magnesium, phosphate, nitrogen, potassium, selenium, calcium, sulfur, iron, copper, zinc, protein, vitamins and / or carbon, etc. In certain embodiments, the iron-trapping pathogens may be supplied with a prebiotic source, which may include, for example, dry animal feed, straw, hay, alfalfa, grains, feed, grass, fruits, vegetables, oats and / or crop residues.
[0192] In certain embodiments, the method includes adding the composition as a dietary supplement to drinking water and / or animal feed. The dietary supplement can have any suitable form, such as gravy, drinking water, beverage, yogurt, powder, granule, paste, suspension, chew, small piece, liquid solution, sweet food, snack, granule, pill, capsule, tablet, pouch or any other suitable delivery form. The dietary supplement may include the composition based on microorganism of the present invention, and optional compounds (such as vitamins, minerals, probiotics, prebiotics and antioxidants). In some embodiments, before being administered to an animal, the dietary supplement may be mixed with feed ingredients or water or other diluents.
[0193] In some embodiments, the composition is suitable for use in grazing land or pasture as well as drinking water and / or feed.
[0194] In certain specific embodiments, the method comprises applying a composition according to the invention to a plant or soil environment in need thereof (i.e., a plant or land environment infected with or at risk of infection with an iron-trapping pathogen). In some embodiments, a plurality of plants and / or their surroundings are treated according to the methods of the invention.
[0195] Application may include contacting the composition directly with the plant, plant part and / or the plant's surrounding environment (e.g., soil or rhizosphere). The microbial product may be applied as a seed treatment or applied to the soil surface, or applied to the surface of the plant or plant part (e.g., applied to the surface of the root, tuber, stem, flower, leaf, fruit or flower). It may be sprayed, poured, sprinkled, injected or diffused in the form of a liquid, dry powder, powder, granule, microparticle, pellet, wettable powder, flowable powder, emulsion, microcapsule, oil, gel, paste or aerosol.
[0196] As used herein, the "surrounding environment" of a plant refers to the soil and / or other culture medium, which may include the rhizosphere, that the plant grows in. In certain embodiments, the surrounding environment does not extend beyond a radius of, for example, at least 5 miles, 1 mile, 1000 feet, 500 feet, 300 feet, 100 feet, 10 feet, 8 feet, or 6 feet from the plant.
[0197] In a specific embodiment, the composition is contacted with one or more roots of the plant. The composition can be applied directly to the roots by spraying or soaking the roots, etc., and / or indirectly to the roots by applying the composition to the soil (or rhizosphere) in which the plant grows. The composition can be applied to the seeds of the plant before or at the time of planting, or to any other part of the plant and / or its surroundings.
[0198] In certain embodiments, the composition is applied to the soil surface without mechanical bonding. The beneficial effects of soil application can be activated by rainfall, sprinkler irrigation, flooding or drip irrigation and subsequently delivered to, for example, the roots of plants.
[0199] The plant and / or its environment can be treated at any point in the process of growing the plant. For example, the immune supplement composition can be applied to the soil before, during or after the seed is planted. It can also be applied at any time during the development and growth of the plant thereafter, including when the plant is flowering, fruiting, and during and / or after the leaves fall off.
[0200] Furthermore, the compositions may be applied prior to infection of the plants by the pests or pathogens or after infection has occurred.
[0201] In one embodiment, the method can be used in large-scale agricultural environments. The method can include applying the composition to a tank connected to an irrigation system for supplying water, fertilizer, or other liquid compositions to crops, orchards, or fields. Therefore, the soil around the plants and / or plants can be treated with the composition in the following manner: for example, soil injection, soil irrigation, or using a center pivot irrigation system, or spraying over the seed furrow, or using a sprinkler or drip irrigation device. Advantageously, the method is suitable for treating hundreds of acres of crops, orchards, or fields at one time.
[0202] In one embodiment, the method can be used in a smaller scale environment, such as a home garden or greenhouse. In such cases, the method can include spraying the composition onto the plants and / or their surroundings using a handheld lawn and garden sprayer. The composition can be mixed with water and, optionally, with other lawn and garden treatments, such as fertilizers and pesticides. The composition can also be mixed into a standard handheld watering can and poured onto the soil.
[0203] The method may include adding materials to promote microbial growth during the application process (e.g., adding nutrients and / or prebiotics to promote the growth of microorganisms). In one embodiment, the nutrient source may include, for example, a source of nitrogen, potassium, phosphorus, magnesium, protein, vitamins and / or carbon. In one embodiment, the prebiotic may include, for example, kelp extract, fulvic acid, humate and / or humic acid. In order to improve or stabilize the effect of the composition, it may be mixed with a suitable adjuvant and then used directly or diluted (if necessary).
[0204] In certain embodiments, the methods comprise applying a composition according to the invention to water and / or an inert or inanimate surface having iron-trapping pathogens therein or thereon.
[0205] The composition can be simply mixed into a water source, such as a pond, water treatment facility, animal drinking container, lake, pond, or fish farm. For biofilms in water sources, such as artificial ponds, water treatment facilities, and other water enclosures, the composition can be applied to surfaces within the pond or enclosure before the water is present.
[0206] The composition can be applied to the surface by spraying using, for example, a spray bottle or a pressurized spray device. The composition can also be applied to the surface using a cloth or brush, wherein the composition is rubbed, spread or brushed onto the surface. In addition, the composition can be applied to the surface by dipping, immersing or submerging the surface into a container containing the composition.
[0207] In one embodiment, the surface is allowed to soak with the composition for a sufficient time to remove pathogens. For example, the soaking time can be as long as 5 minutes to 24 hours or more, as desired.
[0208] In one embodiment, the method further comprises the step of removing the composition and pathogens from the surface. This can be achieved by, for example, flushing or spraying water onto the surface and / or rubbing or wiping the surface with a cloth until the composition and pathogens are cleared from the surface. The flushing or spraying with water can be done before and / or after rubbing or wiping the surface with a cloth. In some embodiments, the spraying is performed at elevated pressure and / or elevated temperature.
[0209] In another embodiment, after application of the composition, mechanical methods can be used to remove pathogens and / or the composition from the surface. For example, a sandblaster, agitator, drill, hammer, sandpaper, or scraper can be used to remove contaminants from a surface that are particularly difficult to remove due to the amount of contaminant or the type of contaminant.
[0210] The methods of the present invention can be used to treat and / or prevent diseases or infections caused by pathogenic microorganisms (including pathogenic biofilms). Examples of such diseases include: diseases and / or infections caused by, for example, Agrobacterium spp. (e.g., Agrobacterium tumefaciens), Dickeya spp. (e.g., D.dadantii), Erwinia spp. (e.g., Erwinia amylovora, Erwinia carotovora), Escherichia spp. (e.g., Escherichia coli), Vibrio spp. (e.g., Vibrio cholerae, Vibrio vulnificus), Shigella spp. spp. (e.g., Shigella flexneri S.flexneri, Shigella dysenteriae S.dysenteriae), Salmonella spp. (e.g., Salmonella enterica S.enterica, Salmonella enteritidis S.newport, Salmonella typhimurium S.typhimurium, Salmonella javana S.javiana), Streptococcus spp. (e.g., Streptococcus pyogenes S.pyogenes, Streptococcus agalactiae S.agalactiae, Group A Streptococcus), Yersinia spp. (e.g., Yersinia pestis Y.pestis), Haemophilus spp. (e.g., Haemophilus influenzae H.influenzae), Klebsiella spp. (e.g., Klebsiella pneumoniae K.pneumoniae), Staphylococcus spp. (e.g., Staphylococcus aureus S.aureus), Mycobacterium spp. (e.g., Mycobacterium tuberculosis M.uberculosis), Neisseria spp. (e.g., Neisseria meningitidis N.meningitidis, Neisseria gonorrhoeae N.gonorrhoeae), Bartonella spp. (e.g., Bartonella quintana B.quintana), Bacillus spp. (e.g., Bacillus anthracis B.anthracis, Bacillus cereus), Serratia spp. (e.g., Serratia marcescens S.marcescens), Pseudomonas spp. (e.g. Pseudomonas aeruginosa P.aeruginosa, Pseudomonas syrinage), Helicobacter spp. (e.g. H. pylori), Legionella spp. (e.g. L. pneumophila), Meningococcus spp., Brucella spp. (e.g. B. abortus), Listeria spp. (e.g. L. monocytogenes), Acinetobacter spp. (e.g. A. baumannii), Francisella spp. (e.g. F. tularensis), Ralstonia spp. (e.g. Ralstonia solanacearum) and / or Haemophilus spp. (e.g. Haemophilus influenzae).
[0211] Specific exemplary human and animal diseases include Legionnaires' disease, meningitis, sepsis, anthrax, plague, gonorrhea, endocarditis, osteomyelitis, cholera, bacteremia, tuberculosis, pneumonia, typhoid, paratyphoid, food poisoning, urinary tract infections, listeriosis, Lyme disease, strep throat, staphylococcal infections, methicillin-resistant Staphylococcus aureus infections (MRSA), hypochlorhydria, and iron deficiency anemia.
[0212] Specific exemplary plant diseases include soft rot, wildfire, wilt, fruit necrotic spot, bacterial spot, crown gall, wilt, stem rot, and fire blight.
[0213] Example
[0214] The present invention and its many advantages can be better understood by the following examples given by way of illustration. The following examples illustrate some methods, applications, embodiments and variations of the present invention. None of them should be considered as limitations of the present invention. For the present invention, a large number of changes and modifications may be made.
[0215] Example 1 - pH growth test of B4 strain
[0216] The B4 strain was spread on tryptic soy agar (TSA) at neutral (6.8) and acidic (4.8) pH levels to look for growth differences, in an effort to determine how it performs in the various pH environments found within the dairy cow digestive system.
[0217] Growth was faster on neutral pH (6.8) compared to acidic plates within 24 hours, but after 48 hours, growth on pH 4.8 agar was equal or faster. Figure 1A to Figure 1B Additionally, when grown on acid agar, it produces large amounts of exopolysaccharides (EPS). Figure 1C . This is the result of environmental pressure.
[0218] Dried B4 spores were also added to sterile PBS adjusted to pH 2.8 and left for 24 hours. They were then plated on neutral (6.8) TSA plates. A lawn of growth appeared, but no EPS was produced (similar to the pH 6.8 plates in Figure 1). This shows that the dried spores were still intact after being exposed to an overall harsh environment. In general, the pH of the growth medium / environment affects the production of EPS.
[0219] Example 2 - EPS
[0220] B4 was grown in liquid medium at pH 4.8 to specifically produce EPS. Putative EPS was isolated from the culture and purified.
[0221] FTIR analysis confirmed that the purified sample was EPS, and HPLC analysis confirmed the presence of a large peak, indicative of sugar oligomers. C=O bonds were also observed via UV absorption.
[0222] Additionally, surprisingly, when the culture was processed for EPS extraction, purple streaks appeared in the cell pellet. When EPS purification was complete, the sample was pink, indicating the presence of pulcherrimin or pulcherriminic acid. Figure 2 .
[0223] Example 3 - Enzyme Assay Test - Amylase
[0224] Amylase is an enzyme that hydrolyzes the glycosidic bonds in starch molecules by converting complex carbohydrates into monosaccharides. Agar (starch) is inoculated with B4 and cultured for growth. Figure 3 After running the plate assay, an orange color is observed around the bacterial growth, indicating starch breakdown. This is a positive amylase test.
[0225] Example 4 - Enzyme Assay Test - Cellulase
[0226] Cellulases are enzymes that convert cellulose into glucose. Carboxymethylcellulose agar (CMCA) plates were used to test the cellulase activity of B4.
[0227] B4 was grown in tryptone soy broth with and without cellobiose. After 48 hours of growth, the liquid culture was streaked onto CMCA plates. After inoculation, once growth appeared on the agar, an iodine solution was introduced to the plates. The yellow transparent area around the bacterial growth indicated the decomposition of cellulose and the presence of cellulase. Figure 4 .
[0228] Example 5 - Detection of siderophores
[0229] The chrome azurol S (CAS) assay was used to detect siderophores from B4 cultures and dried B4 spores. These tests were performed in aerobic and anaerobic environments in different growth media: MRS-sucrose, M23-6, minimal medium with Tween, and minimal medium without Tween. FIG. 5A to FIG. 5C ) and 24 hours ( FIG. 6A to FIG. 6C )Observe multiple plates.
[0230] Siderophores scavenge iron from the Fe-CAS-cetyltrimethylammonium chloride complex and release the CAS dye resulting in a color change from blue to orange. Any observable color change on the CAS agar plate indicates qualitative detection of siderophores.
[0231] All B4 medium cultures tested showed positive responses for siderophore production and activity. MRS-sucrose (the richest medium) produced the strongest activity. There were no differences in siderophore activity between the four medium cultures under aerobic and anaerobic conditions.
[0232] The siderophore activity produced by dried B4 spores was lower compared to that of B4 cultures, which may be due to the dormancy of the spores. The dried spores performed better under aerobic conditions.
[0233] Example 6 - Iron activity determination
[0234] To understand how B4 interacts with iron and to determine differences in iron activity between cultures, an iron assay kit (Sigma-Aldrich) was used to measure the amount of ferrous iron (Fe) present in different B4 cultures. 2+ ) concentration, iron (Fe 3+ ) concentration and total iron concentration.
[0235] Iron is released from the sample by the addition of an acidic buffer. The released iron reacts with the chromogen to produce a colorimetric (593 nm) product proportional to the iron present.
[0236] Figure 7The results in Figures 5 and 6 correlate with the siderophore results reported in Figures 5 to 6, meaning that higher siderophore activity correlates with lower total iron content. For example, MRS-sucrose medium is the richest medium with the highest siderophore activity and the lowest total iron content. Additionally, the minimal medium used is intended to increase the production of pulchermin, which is chelated iron. Higher levels of pulchermin in the culture increase both the iron concentration and the total iron concentration.
Claims
1. A method for controlling iron-trapping pathogens, wherein the method comprises applying a composition comprising one or more iron-trapping components and optionally a carrier to an environment where pathological microorganisms grow.
2. The method of claim 1, further comprising applying an acid to the environment to achieve a pH of 6.8 or less.
3. The method of claim 1, wherein the pathogenic microorganisms capture iron.
4. The method according to claim 2, wherein the pathogenic microorganism is selected from the group consisting of: Agrobacterium, such as Agrobacterium tumefaciens; Dickie's species, such as Dickie's species; Erwinia, such as Erwinia amylovora, Erwinia rot; Escherichia, such as Escherichia coli; Vibrio, such as Vibrio cholerae, Vibrio vulnificus; Shigella, such as Shigella flexneri, Shigella dysenteriae; Salmonella, such as Salmonella enterica, Salmonella enteritidis, Salmonella Newport, Salmonella typhimurium, Salmonella javana; Streptococcus, such as Streptococcus pyogenes, Streptococcus agalactiae, Group A Streptococcus; Yersinia, such as Yersinia pestis; Haemophilus, such as Haemophilus influenzae; Klebsiella, such as Klebsiella pneumoniae, Staphylococcus, such as Staphylococcus aureus; Mycobacterium, such as Mycobacterium tuberculosis; Neisseria, such as Neisseria meningitidis, Neisseria gonorrhoeae; Bartonella, such as Bartonella quinquefasciatus; Bacillus, such as Bacillus anthracis, Bacillus cereus; Helicobacter, such as Helicobacter pylori; Serratia, such as Serratia marcescens; Pseudomonas, such as Pseudomonas aeruginosa, Pseudomonas syringae; Legionella, such as Legionella pneumophila; Meningococcus; Brucella, such as Brucella abortus; Listeria, such as Listeria monocytogenes; Acinetobacter, such as Acinetobacter baumannii; Francisella, such as Francisella tularensis; Ralstonia, such as Ralstonia solanacearum; and / or Haemophilus, such as Haemophilus influenzae.
5. The method of claim 1, wherein the environment comprises a human or animal subject, a plant or soil environment, water, or an inanimate surface.
6. The method of claim 5, wherein the environment is a human or animal subject, and wherein the composition is administered to the subject orally, via injection, inhalation, or topically.
7. The method of claim 5, wherein the environment is a plant or soil environment, and wherein the composition is applied to the plant or soil via an irrigation system or via a spray applicator.
8. The method of claim 5, wherein the environment is an inanimate surface, and wherein after applying the composition to the surface, the composition and the pathogen are removed from the surface.
9. The method of claim 1, wherein the iron-trapping component is a non-pathogenic microorganism that is capable of trapping iron or produces a growth byproduct that is capable of trapping iron.
10. The method according to claim 9, wherein the microorganism is a bacterium of the genus Bacillus.
11. The method of claim 10, wherein the microorganism is Bacillus subtilis B4 NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928.
12. The method of claim 9, wherein the microorganism is applied in the form of spores but grows in the form of a biofilm when in contact with an acidic environment having a pH of 6.8 or less.
13. The method according to claim 1, wherein the method comprises applying an iron-capturing component selected from the group consisting of pulcherrimin, pulcherriminic acid, citrate, citric acid, EDTA ethylenediaminetetraacetic acid, iron EDTA, DTPA diethylenetriaminepentaacetic acid, EDDHA ethylenediamine-di-o-hydroxyphenylacetic acid, N,N-dihydroxy-N,N′-diisopropyladipamide DPH, 2,3-dihydroxybenzoic acid, nitrogen-carrying bacteria, transferrin, enterobactin, pyocyanin, protochelatin, chelate Ferritin, bacteriocin, vibriocin, vibrioferrin, azotocin, aminochelatin, yersin, agarobactin, grapeseed agglutinin, ferrochrome, deferasirox, deferiprone, deferoxamine, fusarin, chrysin, chromobactin, ornithine, rhodotorulic acid, lysine, glutamic acid, gluconic acid, iron oxyhydroxide minerals, ferrihydrite, magnetite, hematite, goethite, siderite hydroxamate, catecholase, salicylate, carboxylate, mugineic acid, ferulic acid, caffeic acid and / or nicotinamide.
14. The method of claim 1, wherein the composition further comprises one or more microbial growth byproducts selected from the group consisting of biosurfactants, enzymes, organic acids, fatty acids, amino acids, proteins, peptides, alcohols, polyketides, natural antibiotics, aldehydes, amines, sterols, and vitamins.
15. A composition for controlling iron-trapping pathogens, the composition comprising one or more iron-trapping ingredients, and optionally a carrier.
16. The composition of claim 15, further comprising an amount of an acid to adjust the pH of the composition to 6.8 or less.
17. The composition of claim 15, wherein the iron-trapping component is a non-pathogenic microorganism that is capable of trapping iron or produces a growth byproduct that is capable of trapping iron.
18. The composition of claim 16, wherein the microorganism is a bacterium of the genus Bacillus.
19. The composition of claim 18, wherein the microorganism is Bacillus subtilis B4 NRRL B-68031 or Bacillus amyloliquefaciens NRRL B-67928.
20. The composition of claim 15, wherein the microorganism is in spore form or biofilm form.
21. The composition of claim 15, wherein the iron-trapping component is selected from the group consisting of pulcherrimin, pulcherriminic acid, citrate, citric acid, EDTA ethylenediaminetetraacetic acid, iron EDTA, DTPA diethylenetriaminepentaacetic acid, EDDHA ethylenediamine-di-o-hydroxyphenylacetic acid, N,N-dihydroxy-N,N′-diisopropyladipamide DPH, 2,3-dihydroxybenzoic acid, nitrogen-carrying bacteria, transferrin, enterobactin, pyocyanin, protochelatin The invention can be used to treat schizolin, chelatin, chelatin, bacteriocin, vibriocin, vibrioferrin, azotocin, aminochelatin, yersin, ferrochrome, deferasirox, deferiprone, deferoxamine, fusarin, chrysin, chromatin, ornithine, rhodotorulic acid, lysine, glutamic acid, gluconic acid, ferric oxyhydroxide minerals, ferrihydrite, magnetite, hematite, goethite, siderite, hydroxamate, catecholase, salicylate, carboxylate, mugineic acid, ferulic acid, caffeic acid and / or nicotinamide.
22. The composition of claim 15, further comprising a germination enhancer, wherein the germination enhancer is L-alanine, L-leucine, or manganese.
23. The composition of claim 15, further comprising one or more microbial growth byproducts selected from the group consisting of biosurfactants, enzymes, organic acids, fatty acids, amino acids, proteins, peptides, alcohols, polyketides, natural antibiotics, aldehydes, amines, sterols, and vitamins.
24. The composition of claim 15, further comprising a nutrient or a prebiotic.
